

Sen. Carson, Dist 14
Sen. Whitley, Dist 15
Sen. Avard, Dist 12
May 16, 2023
2023-1893s
05/08

Floor Amendment to HB 611-FN

1 Amend the title of the bill by replacing it with the following:

2

3 AN ACT relative to eligibility criteria for the therapeutic cannabis program and relative to the
4 prohibition on the sale of hemp products containing certain levels of THC.

5

6 Amend the bill by replacing all after section 2 with the following:

7

8 3 New Subparagraph; Therapeutic Cannabis Medical Oversight Board; Duties. Amend RSA
9 126-X:12, IV by inserting after subparagraph (g) the following new subparagraph:

10 (h) Developing, reviewing, and updating cannabis product labels and educational
11 material about the risks of cannabis use to be provided to qualifying patients by alternative
12 treatment centers and certifying medical providers.

13 4 New Section; Agriculture, Horticulture and Animal Husbandry; Hemp; Hemp-Derived
14 Products Containing THC Prohibited. Amend RSA 439-A by inserting after section 439-A:3 the
15 following new section:

16 439-A:4 Hemp-Derived Products Containing THC Prohibited. Nothing in this chapter shall be
17 construed to authorize the sale of products that are derived from hemp which contain natural or
18 synthetic tetrahydrocannabinol (THC) greater than 0.3 percent on a dry weight basis, which appear
19 in any formulation, including delta-8 THC, delta-9 THC, or any other THC isomer variant.

20 5 Effective Date. This act shall take effect 60 days after its passage.

Amendment to HB 611-FN
- Page 2 -

2023-1893s

AMENDED ANALYSIS

This bill removes the requirement that severe pain be resistant to other treatment options in order to be considered a qualifying medical condition for therapeutic cannabis. The bill also prohibits the sale of hemp products containing certain amounts of THC.